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Background: Raised blood pressure (BP) is associated with the incidence of metabolic syndrome (MetS). It is
unknown if subjects with different BP levels may develop certain components of MetS over time. We investigated
the incidence of MetS relative to different levels of BP over a 5-year period in a Chinese population in Tongren
Hospital, Beijing.
Methods: During the period of 2006–2011, we recruited 2,781 participants with no MetS, or self-reported type 2
diabetes, dyslipidemia, hypertension, or cardiovascular disease at baseline. Association rule was used to identify the
transitions of MetS components over time.
Results: The incidence of MetS at follow-up was 9.74% for men and 3.21% for women in the group with optimal
BP; 10.29% and 7.22%, respectively, in the group with normal BP; 10.49% and 10.84%, respectively, in the group
with high-normal BP; and 14.48% and 23.21%, respectively in the group with high BP. The most common transition
was from healthy to healthy in the groups with optimal or normal BP (17.9–49.3%), whereas in the high-normal BP
group, 16.9-22.1% of subjects with raised BP returned to healthy status or stayed unchanged, while 13.8-21.4% of
people with high BP tended to develop raised fasting glucose levels.
Conclusions: The incidence of MetS increased in parallel with the increase in BP. People with optimal and normal
BP levels were less susceptible to developing MetS over time, whereas abnormal BP seemed to be a pre-existing
phase of MetS. High-normal BP was a crucial status for MetS prevention.
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Metabolic syndrome (MetS) is a complex medical condi-
tion comprising five inter-related risk factors within an
individual: obesity, hypertension, hypertriglyceridemia,
low high-density lipoprotein cholesterol (HDL-C), and
hyperglycemia [1,2]. It is a growing public-health issue
and with approximately one quarter of the world adult
population having the disorder [3]. Several studies have
indicated that insulin resistance is a major underlying
cause of MetS [4-6]. And MetS is frequently reported to* Correspondence: guoxiuh@ccmu.edu.cn
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reproduction in any medium, provided the orbe in association with cardiovascular disease (CVD)
[7-10]. But the clinical value of MetS and its effect on a
patient life is still controversial [11,12]. As a result, there
is an absence of conclusive recommendations for pa-
tients with MetS [13].
Hypertension may trigger the pathogenesis of CVD,
and has been shown to be a key factor of MetS [14]. The
Framingham Heart Study showed that hypertension
played a central role in MetS, and was the most com-
monly associated risk factor for MetS [15]. Subjects with
certain combinations of MetS components showed
greater arterial changes, and MetS might be a conse-
quence of raised blood pressure (BP). Thus, MetS pre-
dicts the onset of CVD, as it has deleterious effects
associated with central arterial aging [16,17].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The results of logistic regression model
Variable B S.E. Wald d.f. P value OR 95% CI for OR
Lower Upper
Sex −0.115 0.125 0.845 1 0.358 0.891 0.698 1.139
Age 0.026 0.005 25.670 1 <0.001 1.027 1.016 1.037
BMI 0.340 0.022 232.297 1 <0.001 1.406 1.345 1.468
FPG 0.060 0.081 0.542 1 0.461 1.062 0.905 1.246
SBP 0.024 0.004 32.247 1 <0.001 1.024 1.016 1.032
TG 0.447 0.072 38.876 1 <0.001 1.564 1.359 1.800
HDL-C −1.412 0.219 41.701 1 <0.001 0.244 0.159 0.374
Constant −12.010 0.857 196.490 1 <0.001 0.000
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risk factors underlie the pathophysiology of MetS, there
have been few studies investigating which MetS compo-
nents tend to cluster dominantly, and how the state of
each risk factor changes over time [15,18].
In the present study, we classified subjects with differ-
ent levels of BP into four groups at baseline in order to
investigate: 1) whether there is a correlation between the
level of BP and the incidence of MetS; 2) what risk fac-
tors tend to develop at each level of BP; and 3) how
these risk factors change with time.
Methods
Survey methodology and laboratory tests
At Beijing Tongren Hospital, subjects’ health records of
routine physical check-ups have been computerized
since 2006. We selected the records of adult visitors who
had a physical check-up, using in 2006/2007 as the base-
line, and 2010/2011 as the end point. Totally, there were
7,512 people who had check-up records both at baseline
and the follow-up. 3,406 subjects with missing data of
weight, height, systolic or diastolic blood pressure (SBP,
DBP), fasting blood glucose (FPG), triglycerides(TG), or
HDL-C were excluded. 950 subjects with any medical
history of stroke, heart failure, angina pectoris or myo-
cardial infarction, or in use of any hypoglycemic, anti-
dislipidemic, or antihypertensive treatment were ex-
cluded as well. 975 subjects who had MetS at baseline
were ruled out. The final cohort was composed of 2,781
participants.
The physical check-ups included measurements of
weight, height, and BP, and analyses of blood biochemis-
try parameters. Body mass index (BMI) was calculated
as weight/height2 (kg/m2). Patients were given a five-
minute rest in a seated position before systolic and dia-
stolic blood pressure (SBP, DBP) were measured with a
mercury sphygmomanometer.
The blood biochemical analyses included FPG and
HDL-C. The blood samples were taken from the cubital
vein in the morning after 8 o’clock. Each individual con-
firmed that there had been no food intake for least
10 hours. The samples were analyzed immediately after
pre-treatment or stored at -80°C for further analysis.
Serum HDL-C concentration was measured photomet-
rically (Hitachi 704; Roche, Mannheim, Germany), and
TG and FPG concentrations were determined enzymati-
cally (Hitachi 717; Roche Diagnostics), with all analy-
ses performed in accordance with the manufacturer’s
recommendations.
Definition of metabolic syndrome
Diagnostic criteria for the assessment of MetS compo-
nents were defined according to the Joint Scientific State-
ment of MetS [19]. However, as waist circumference wasnot obtained, BMI was taken as a substitute for the com-
ponent of obesity, as it was reported previously that BMI
was strongly associated hypertension and CVD in a popu-
lation of northern Chinese [20]. The diagnosis criteria
used in our research were as follows:
 Overweight: BMI ≥ 25 and < 30 kg/m2; obese: BMI ≥
30 kg/m2 [21];
 Raised TG level (drug treatment for raised
triglyceride level is an alternative indicator): ≥
150 mg/dl (1.7 mmol/L) [19];
 Reduced HDL-C level (drug treatment for reduced
HDL-C level is an alternative indicator): < 40 mg/dl
(1.0 mmol/L) in male; < 50 mg/dl (1.3 mmol/L) in
female [19];
 Raised BP (antihypertensive drug treatment in a
patient with a history of hypertension is an alternate
indicator): SBP ≥ 130 mmHg and/or DBP ≥
85 mmHg [19];
 Raised FPG level (drug treatment of raised glucose is an
alternative indicator): ≥ 100 mg/dL (5.6 mmol/L) [19];
Participants fulfilling at least three out of these five
components were diagnosed as having MetS.
Layered approach for blood pressure levels at baseline
Subjects were divided into subgroups according to their BP
at entry time using the WHO classification criteria [22]. To
avoid the overlap of “optimal pressure” and “normal pres-
sure” in the WHO criteria, we defined optimal pressure as
SBP < 120 and DBP < 80 mmHg; normal BP as SBP ≥120
and <130 mmHg, and/or DBP ≥80 and <85 mmHg; high-
normal BP as SBP ≥130 and <140 mmHg, and/or DBP ≥85
and <90 mmHg; and high BP as either SBP ≥140 or DBP
≥90 mmHg. When a visitor’s SBP and DBP were in differ-
ent categories, the higher category was used.
Statistical analysis
Categorical data are presented as percentages, and con-
tinuous data as mean plus standard deviation (SD). The
Table 2 The profile of MetS components in male subjects aged 18–49 of different blood pressure group at baseline
(n = 965)
Characteristic Optimal BP (n = 342) Normal BP (n = 367) High-normal BP (n = 113) High BP (n = 66)
Baseline Follow-up P-value Baseline Follow-up P-value Baseline Follow-up P-value Baseline Follow-up P-value
BMI, kg/m2 23.46 ± 3.10 24.35 ± 3.15 <0.001 23.67 ± 2.83 24.44 ± 2.87 <0.001 24.10 ± 3.07 24.50 ± 2.93 0.001 24.94 ± 2.96 25.57 ± 3.22 <0.001
SBP, mmHg 103.70 ± 7.33 112.51 ±11.49 <0.001 116.04 ± 6.74 117.32 ±10.61 0.043 125.88 ± 7.05 121.82 ±12.04 0.001 131.85 ±12.76 127.611±15.06 0.001
DBP, mmHg 68.86 ± 4.42 74.61 ± 8.94 <0.001 77.41 ± 4.28 77.14 ± 8.04 0.557 82.26 ± 4.28 79.93 ±10.06 0.017 92.99 ± 7.10 85.30 ± 9.61 <0.001
HDL-C, mmol/L 1.34 ± 0.29 1.24 ± 0.29 <0.001 1.34 ± 0.27 1.27 ± 0.30 <0.001 1.38 ± 0.27 1.36 ± 0.31 0.295 1.35 ± 0.24 1.30 ± 0.28 0.003
TG, mmol/L 1.36 ± 1.17 1.61 ± 1.37 <0.001 1.28 ± 0.73 1.64 ± 1.61 <0.001 1.33 ± 0.98 1.47 ± 0.99 0.084 1.39 ± 0.97 1.60 ± 1.03 0.003
FPG, mmol/L 5.12 ± 0.46 5.24 ± 0.53 <0.001 5.26 ± 0.76 5.37 ± 0.82 0.006 5.28 ± 0.53 5.34 ± 0.81 0.279 5.37 ± 0.68 5.67 ± 1.55 0.007
BMI body mass index, SBP, DBP systolic / diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, TG triglyceride, FPG fasting plasma glucose. P-value is
based on paired t-test.
Huo et al. BMC Public Health 2013, 13:912 Page 3 of 9
http://www.biomedcentral.com/1471-2458/13/912five individual risk factor states were analyzed at baseline
and follow-up.
We performed association rule to analyze the changes
in MetS component or their combinations during the
five-year period in our cohort. As the subjects at base-
line were people with two or less MetS components,
there were 16 (i.e. C05 þ C15 þ C25) possible states at base-
line, with 32 (i.e. 25) possible states at follow-up. Theor-
etically, there were 512 (i.e. 16 × 32) possible transitions
between states from baseline to follow-up. The data are
presented as transitions of states. The module of associ-
ation rule in SAS software (version 9.1; SAS Institute,
Chicago, IL, USA) was used to generate the change from
a risk factor state to another, with “healthy” defined as
being the state free of MetS component. Data prepar-
ation and descriptive statistics were using the same
software.Ethics statement
This study was approved by the ethics committee of the
Capital Medical University of China, and performed in
accordance with the principles of Declaration of Helsinki
(reference no. 2013SY26).Consent
Written informed consent was obtained from the patient for
publication of this report and any accompanying images.Table 3 The profile of MetS components in male subjects age
baseline (n = 249)
Characteristic Optimal BP (n = 66) Normal BP (n = 88)
Baseline Follow-up P-value Baseline Follow-up P-
BMI, kg/m2 24.42 ± 3.16 24.49 ± 3.24 0.753 24.57 ± 2.57 24.88 ± 2.73 0
SBP, mmHg 103.11 ± 7.33 111.71 ±14.93 <0.001 115.23 ± 6.99 121.38 ±14.05 <
DBP, mmHg 68.86 ± 4.87 74.05 ±10.11 <0.001 77.50 ± 4.29 80.17 ±10.67 0
HDL-C, mmol/L 1.42 ± 0.28 1.35 ± 0.29 0.003 1.34 ± 0.31 1.29 ± 0.35 0
TG, mmol/L 1.43 ± 0.98 1.43 ± 0.77 0.998 1.42 ± 0.87 1.60 ± 1.35 0
FPG, mmol/L 5.67 ± 1.21 5.72 ± 1.13 0.719 5.74 ± 1.00 5.88 ± 0.85 0
BMI body mass index, SBP, DBP systolic/diastolic blood pressure, HDL-C high-density
based on paired t-test.Results
At baseline, of the 2,781 subject, 43.7% were mens with
the median age of 36.0 years-old (39.0 ± 11.1, mean ±
SD), while 56.3% were women with the median age of
39.0 years-old (39.3 ± 10.2). The follow-up interval was
4.83 ± 0.44 years for men and 4.76 ± 0.48 years for
women, respectively. To adjust for confounding vari-
ables, gender, age, BMI, FPG, SBP, TG and HDL-C at
baseline were included in binary logistic regression. The
results are shown in Table 1.
The components of MetS in the population at baseline
and follow-up were grouped by BP level at baseline
(Tables 2, 3, 4 and 5). Subjects were divided in two age
groups (18–49 and ≥50), which stands for young and old
people. The incidence of MetS at follow-up was analyzed
by gender and BP level at baseline (Figures 1 and 2).
Young men with optimal, normal and high-normal BP
had a higher incidence of MetS compared with women
in the same groups (23.98% vs. 7.76%, 24.25% vs. 12.84%
and 29.20% vs. 22.22%, respectively). The numbers of
each gender were almost the same in the high BP group
(45.45% vs. 43.08%). Whereas old men with optimal,
normal and high-normal BP had a higher incidence of
MetS compared with women in the same groups
(27.27% vs. 22.22%, 38.64% vs. 31.71, respectively). The
numbers of each gender were almost the same in the
high-normal and high BP group (27.78% vs. 28.00%,
42.37% vs. 44.74).d 50 and above with different blood pressure group at
High-normal BP (n = 36) High BP (n = 59)
value Baseline Follow-up P-value Baseline Follow-up P-value
.008 23.57 ± 2.59 24.02 ± 2.67 0.015 24.03 ± 2.85 24.44 ± 3.19 0.004
0.001 127.50 ± 5.67 130.28 ±11.93 0.151 132.88 ±14.72 127.14 ±15.03 0.004
.025 80.97 ± 4.44 80.25 ±10.82 0.665 89.07 ± 7.74 83.24 ± 7.87 <0.001
.097 1.45 ± 0.28 1.38 ± 0.31 0.060 1.46 ± 0.37 1.39 ± 0.33 0.036
.118 1.33 ± 0.75 1.39 ± 0.72 0.618 1.34 ± 0.80 1.42 ± 0.74 0.396
.088 5.67 ± 1.32 5.64 ± 0.77 0.897 5.63 ± 0.94 5.83 ± 1.04 0.011
lipoprotein cholesterol, TG triglyceride, FPG fasting plasma glucose. P-value is
Table 4 The profile of MetS components in female subjects aged 18–49 of different blood pressure group at baseline
(n = 1 323)
Characteristic Optimal BP (n = 838) Normal BP (n = 366) High-normal BP (n = 54) High BP (n = 65)
Baseline Follow-up P-value Baseline Follow-up P-value Baseline Follow-up P-value Baseline Follow-up P-value
BMI, kg/m2 21.48 ± 2.67 22.17 ± 2.83 <0.001 22.24 ± 2.71 22.83 ± 2.82 0.097 22.96 ± 2.63 23.63 ± 2.75 0.025 23.76 ± 2.36 24.27 ± 2.68 0.011
SBP, mmHg 101.03 ± 7.43 107.19 ±11.82 <0.001 115.48 ± 7.09 114.35 ±12.32 <0.001 124.63 ± 7.32 119.80 ±14.39 0.025 129.00 ±14.66 126.88 ±16.51 0.265
DBP, mmHg 66.08 ± 5.12 70.23 ± 7.97 <0.001 77.79 ± 4.14 75.09 ± 8.39 <0.001 82.31 ± 3.46 79.98 ± 9.62 0.089 90.31 ± 8.00 83.55 ±11.48 <0.001
HDL-C, mmol/L 1.64 ± 0.33 1.58 ± 0.33 <0.001 1.62 ± 0.34 1.57 ± 0.38 <0.001 1.66 ± 0.27 1.51 ± 0.33 <0.001 1.62 ± 0.31 1.53 ± 0.35 0.010
TG, mmol/L 0.86 ± 0.48 0.98 ± 0.67 <0.001 1.03 ± 0.82 1.12 ± 0.83 0.014 1.02 ± 0.41 1.23.± 0.78 0.023 1.13 ± 0.60 1.32 ± 0.72 0.028
FPG, mmol/L 5.05 ± 0.44 5.12 ± 0.47 <0.001 5.20 ± 0.47 5.26 ± 0.64 0.039 5.30 ± 0.54 5.36 ± 0.71 0.324 5.22 ± 0.39 5.37 ± 0.67 0.066
BMI body mass index, SBP, DBP systolic/diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, TG triglyceride, FPG fasting plasma glucose. P-value is
based on paired t-test.
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were identified (Figures 3 and 4). As the sample size was
too small after grouping by age. The association rule is
applied without sub-stratification of age. The support
rate of transitions (defined as the percentage of initial
state to another state in all possible transitions) was ex-
amined in the period 2006/2007 to 2010/2011 in the dif-
ferent subgroups at baseline. For visual simplicity, the
five most commonly observed transitions are shown
in the parts of the relevant figures. The most common
transition in both genders with optimal and normal BP
was “healthy” to “healthy”, whereas for the high-normal
BP group, the main transition was from “high BP” to
“healthy”, and for the group with high BP, the major
transition was from “high BP” to “high BP with high
fasting glucose”. The rates of transition are shown for
each gender and BP group. The confidence rate means
how many cases transitioned within a certain status. For
example, 244 male subjects were initially healthy at base-
line, and 142 (53.79%) of these stayed healthy, while 23
(8.71%) transitioned to hypertension and high fasting
glucose at the end of the observation period.
Discussion
The present cohort study, comprising 2,781 subjects in
Beijing Tongren Hospital, focused on detecting how the
incidence of MetS changed relative to BP level and what
MetS components tend to emerge and change during aTable 5 The profile of MetS components in female subjects a
baseline (n = 244)
Characteristic Optimal BP (n = 99) Normal BP (n = 82)
Baseline Follow-up P-value Baseline Follow-up P-
BMI, kg/m2 24.11 ± 2.06 23.43 ± 3.05 0.451 23.49 ± 2.46 23.52 ± 2.53 0
SBP, mmHg 103.23 ± 6.56 111.02 ±13.12 <0.001 116.46 ± 7.00 118.46 ±15.21 0
DBP, mmHg 67.53 ± 4.76 71.66 ± 8.13 <0.001 78.17 ± 4.05 74.27 ± 8.71 <
HDL-C, mmol/L 1.64 ± 0.36 1.60 ± 0.38 0.060 1.63 ± 0.36 1.51 ± 0.32 <
TG, mmol/L 1.19 ± 0.70 1.35 ± 0.80 0.007 1.33 ± 1.07 1.49 ± 0.88 0
FPG, mmol/L 5.26 ± 0.53 5.27 ± 0.55 0.868 5.37 ± 0.53 5.42 ± 0.48 0
BMI body mass index, SBP, DBP systolic / diastolic blood pressure, HDL-C high-densi
based on paired t-test.5-year follow-up period. Our study revealed that the
higher the BP at baseline, the higher the incidence of
MetS at a later stage. We identified that people with dif-
ferent levels of BP would develop different combinations
of risk factors. On analyzing the change in risk factors,
we found that people with high BP tended to have im-
paired fasting glucose as the most common additional
and new-onset MetS component, and that people with a
lower BP level developed raised BP as the initial risk fac-
tor of MetS.
SBP and DBP of people with optimal and normal
blood pressure at baseline tended to increase with time,
while the SBP or DBP dropped in the subjects with
high-normal and high blood pressure, according to ori-
ginal Tables 1 and 2. People with high-normal and high
blood pressure may be more alert to their health as
health education and promotion programs are popular
in varies media in Beijing, possible actions could be
intentionally or unintentionally taken, and their SBP/
DBP is, therefore, controlled or even lowered.
An association between raised BP and MetS has been
reported as the most common MetS component [23], or
even serves as an independent predictor for CVD [24].
Several studies with structural equation modeling indi-
cated that hypertension might play both a direct and in-
direct roles in the development of MetS [25-27].
However, physiologically, it is not easy to connect
insulin-resistance with MetS [28]. In the present study,ged 50 and above of different blood pressure group at
High-normal BP (n = 25) High BP (n = 38)
value Baseline Follow-up P-value Baseline Follow-up P-value
.858 22.55 ± 2.29 23.10 ± 2.92 0.027 24.17 ± 3.18 24.09 ± 3.53 0.699
.273 128.40 ± 4.73 124.44 ±12.93 0.143 139.34 ±15.03 134.76 ±19.41 0.149
0.001 79.80 ± 5.30 77.20 ± 8.23 0.215 86.18 ± 9.11 80.16 ±11.85 0.002
0.001 1.85 ± 0.35 1.68 ± 0.30 0.004 1.72 ± 0.28 1.54 ± 0.28 <0.001
.059 1.07 ± 0.34 1.25 ± 0.66 0.080 1.27 ± 0.58 1.34 ± 0.59 0.456
.474 5.24 ± 0.44 5.43 ± 0.47 0.047 5.51 ± 0.47 5.65 ± 0.66 0.173
ty lipoprotein cholesterol, TG triglyceride, FPG fasting plasma glucose. P-value is
23.98 24.25
29.20
45.45
7.76
12.84
22.22
43.08
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
40.00
45.00
50.00
Optimal BP Normal BP High-normal BP High BP
ac
cu
m
u
la
te
d
 in
ci
d
en
ce
 (
%
)
Male
Female
#
*, #
*
*
*
*,#
Figure 1 The accumulated incidence of MetS in subjects aged 18–49, stratified by gender and blood pressure level. *Compared with
optimal BP group of same gender using χ2 test, P < 0.001. #Compared with male counterpart using χ2 test, P < 0.001.
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http://www.biomedcentral.com/1471-2458/13/912we found that people with optimal and normal BP
tended to have a relative lower incidence of MetS after
5 years comparing with people with high BP, and were
less susceptible to developing the disorder. Most sub-
jects who started off as “healthy” remained “healthy”,
similar to a previous study in a German population [29].
However, abnormal BP tended to be the first risk factor
for MetS. About 17% of subjects with high-normal BP
returned to “healthy”, while 12% continued to be in the
condition.
By analyzing the shifts in MetS components, we found
that raised BP was the most common risk factor for all27.27
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Figure 2 The accumulated incidence of MetS in subjects aged ≥50, st
optimal BP group of same gender using χ2 test, P < 0.001. #Compared withgroups. Previous studies have also shown that hypertension
was the most important MetS component for men and
one of the three most important components for women
[30]. Previous study suggested that prehypertension (SBP =
120–139 mmHg, and/or DBP = 80–89 mmHg) was pre-
dictive for risk of MetS [31].
In our study, subjects with high BP tended to have im-
paired fasting plasma glucose as a secondary risk factor.
This is accordance with other studies, which found that
raised fasting glucose was the second common compo-
nent of MetS and people with MetS tended to have
a disorder of glucose metabolism [32]. Prehypertension27.78
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29.17
6.62
3.43 3.43 3.19
52.42
31.40
6.17 6.17
15.12
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
(n=119) (n=27) (n=14) (n=14) (n=13)
Support (%) Confidence (%)
24.40
6.37 5.27 4.18 2.86
44.40
11.60
25.26
7.60
5.20
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
(n=111) (n=29) (n=24) (n=19) (n=13)
Support (%) Confidence (%)
17.45
11.41
6.04 6.04 5.37
35.62
23.29
19.15 19.15
17.02
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
(n=26) (n=17) (n=9) (n=9) (n=8)
Support (%) Confidence (%)
12.87
9.90
7.92
5.45 5.45
33.33
24.69
19.75
14.10 13.58
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
(n=26) (n=20) (n=16) (n=11) (n=11)
Support (%) Confidence (%)
A B
C D
Figure 3 The support and confidence rate of the top five transitions in female subjects from 2006/2007 to 2010/2011 in different
blood pressure groups. The support and confidence rate of the top five transitions in male subjects from 2006/2007 to 2010/2011 in different
blood pressure groups. (A) in optimal BP group; (B) in normal BP group; (C) in normal-high BP group; (D) in high BP group. Abbreviations: H,
health, with the absence of any MetS components; P, high blood pressure; G, high fasting plasma glucose; I, elevated body mass index; T, raised
triglycerides level.
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http://www.biomedcentral.com/1471-2458/13/912may be an end-point related to each of the other four
components. It is mainly a consequence of systemic low-
grade inflammation and apoA-I dysfunction. In addition
to the five components of MetS, prothrombotic and
proinflammatory states are essential features based on the
evidence of impaired function of HDL and apo A-I parti-
cles is discernible by biological evidence of functional de-
fectiveness via outcomes studies and/or correlations with
inflammatory and anti-inflammatory biomarkers [33]. The
aggregation to lipoprotein (Lp)(a) of apolipoprotein (apo)
A-I underlies HDL dysfunction, and is an independent risk
factor of magnitude similar to conventional components
of MetS [34]. Some studies indicated that proinfla-
mmatory state and oxidative stress are crucial for
cardiometabolic disorders. Factors such as creatinine,
platelet-activating factor, acetylhydrolase, thyroid stimulat-
ing hormone, acylation-stimulating protein, asymmetricdimethylarginine, and serum lipoprotein (Lp) (a) are key
to trigger systemic low-grade inflammation and enhanced
autoimmune reactions, which may induce impaired glu-
cose and metabolic syndrome [35].
In most circumstances, “healthy” was the predominant
state, and people with a single risk factor tended to re-
turn to the “healthy” state. High-normal BP was a crucial
status for MetS prevention. As hypertension has a low
rate of awareness in China, it is an important prevent-
able risk factor for MetS and CVD events [36].
The strengths of this research were that it was a longi-
tudinal study of 5 years in a Chinese population with
data of relatively good quality. The limitation was the
lack of waist circumference as an indicator for central
obesity; however, we used BMI for substitute according
to the WHO expert consultation [21]. As Tongren Hos-
pital is located in the center of Beijing, bias may be that
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Figure 4 The support and confidence rate of the top five transitions in male subjects from 2006/2007 to 2010/2011 in different blood
pressure groups. The support and confidence rate of the top five transitions in female subjects from 2006/2007 to 2010/2011 in different blood
pressure groups. (A) in optimal BP group; (B) in normal BP group; (C) in normal-high BP group; (D) in high BP group. Abbreviations: H, health,
with the absence of any MetS components; P, high blood pressure; G, high fasting plasma glucose; I, elevated body mass index; T, raised
triglycerides level.
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http://www.biomedcentral.com/1471-2458/13/912there were more people with an urban life style recruited
for the research. In addition, this study was based on a
population attending for routine health check-up. Fur-
ther studies using the general population would be
desirable.
Conclusions
The incidence of MetS augments with the elevation of
BP over time. People with optimal and normal BP were
less susceptible than people with higher BP to develop-
ing MetS. Although most cases stayed “healthy”, they
tended to have abnormal BP as the initial sign of MetS.
High-normal BP was a crucial status for MetS preven-
tion as some of the cases were able to return “healthy”.
In the high BP group, high fasting glucose was a second-
ary risk factor. More efforts are needed to identifyeffective intervention for individuals with abnormal BP
to prevent those developing MetS.
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